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The assumption that CYP2D1 is the corresponding rat cytochrome to human CYP2D6 has been revis-
ited using recombinant proteins in direct enzyme assays. CYP2D1 and 2D2 were incubated with
known CYP2D6 substrates, the three morphine precursors thebaine, codeine and (R)-reticuline.
Mass spectrometric analysis showed that rat CYP2D2, not 2D1, catalyzed the 3-O-demethylation
reaction of thebaine and codeine. In addition, CYP2D2 incubated with (R)-reticuline generated four
products corytuberine, pallidine, salutaridine and isoboldine while rat CYP2D1 was completely inac-
tive. This intramolecular phenol-coupling reaction follows the same mechanism as observed for
CYP2D6. Michaelis–Menten kinetic parameters revealed high catalytic efﬁciencies for rat CYP2D2.
These ﬁndings suggest a critical evaluation of other commonly accepted, however untested, CYP2D1
substrates.
 2012 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Human CYP2D6 is involved in the oxidation of about 30% of
clinically relevant drugs including the morphine precursor codeine
[1,2]. The enzyme has been connected to a phenomenon known as
the debrisoquine/sparteine metabolism of drug oxidation which is
caused by aberrant metabolism patterns due to the absence or
deﬁciency of functional allelic variants of CYP2D6 [3]. At least
112 allelic variants of CYP2D6 have been described since the dis-
covery of the genetic polymorphism resulting in a total of four
individual phenotypes: poor, intermediate, extensive and ultra-
rapid metabolizers [4]. Considering the multitude of clinically
relevant compounds that are metabolized by human CYP2D6, drug
dosages tailored towards individual phenotypes are currently dis-
cussed [2].
In the past, an in vitro model to test possible CYP2D6 substrates
utilized microsomal preparations of different rat strains that differ-
entially express CYP2D1, the proposed rat orthologue to CYP2D6 [5].
Using this approach, liver microsomes obtained from Dark-Agoution behalf of the Federation of Euro
ultiple reaction monitoring;
.M. Kutchan).
tment of Pharmacology and
l Glenn Highway, Dayton, OH
nuscript.rats deﬁcient in CYP2D1 were found to convert the two morphine
precursors, thebaine and codeine, less efﬁciently as microsomes
from Sprague–Dawley rats expressing CYP2D1 [6,7].
Our interest in elucidating mammalian enzymes involved in
mammalian morphine biosynthesis led us to test rat CYP2D1 in di-
rect enzyme assays similar to the CYP2D6 approach described pre-
viously [8]. Surprisingly, rat CYP2D1 was not capable of catalyzing
the 3-O-demethylation of thebaine and codeine nor the phenol-
coupling reaction of (R)-reticuline. The rat genome was subse-
quently searched and ﬁve isoforms were identiﬁed: CYP2D2,
CYP2D3, CYP2D4, CYP2D5 and CYP2D18 among which CYP2D2
was described as poorly expressed in the Dark-Agouti rat strain
next to CYP2D1 with similar catalytic activities as observed for
human CYP2D6 [9,10]. We obtained microsomes containing rat
CYP2D2 from a commercial source and describe herein its
enzymatic characterization using the three morphine precursors
(R)-reticuline, thebaine and codeine.
2. Materials and methods
2.1. Enzymes
CYP2D1 and CYP2D2 were purchased from BD Biosciences
(Woburn, MA). For conﬁrmation of amino acid sequences, the
P450 enzymes were subjected to SDS–PAGE on a 10% (w/v) acryl-
amide gel. Protein bands at approximately 55–58 kDa were
excised, eluted and sequenced using a 6520 QTOF with Chip Cube
(Agilent, Santa Clara, CA).pean Biochemical Societies.
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Reactions were conducted in a total volume of 250 ll containing
100 mM potassium phosphate buffer (pH 7.4), 15 lg L-a-dilauroyl-
sn-glycero-3-phosphocholine, 1 mM NADP+, 10 mM glucose 6-
phosphate, 1 unit/ml glucose-6-phosphate dehydrogenase (yeast),
1000 units/ml catalase (bovine liver), 10 lg bovine erythrocyte
superoxide dismutase, and 0.25–50 lM alkaloidal substrate. Reac-
tions were started by adding 5–30 pmol P450 enzyme (BD Biosci-
ences) and incubated for 10–120 min at 37 C. Extraction of
alkaloids was conducted as previously described [8]. Alkaloids were
analyzed by LC–MS/MS. Kinetic parameters were estimated by non-
linear regression with GraphPad Prism. The debrisoquine oxidation
assay was prepared according to Hiroi et al. 2002 [10]. Reactions
were conducted in a total volume of 250 ll containing 100 mM
potassium phosphate buffer (pH 7.4), 0.8 mM NADPH, and 4 lM
debrisoquine or alkaloidal substrate. Reactionswere started by add-
ing 10 pmol P450 enzyme (BD Biosciences), incubated for 10–
120 min and stopped with 25 ll 10% trichloroacetic acid. After cen-
trifugation, the supernatant was analyzed by LC–MS/MS.
2.3. LC–MS/MS analysis
Enzyme activities were analyzed with a 4000 QTRAP LC–TIS–
MS–MS (Agilent) system using the multiple reaction monitoring
(MRM) in positive ionization mode. Compound dependent parame-
ters (collision energy, declustering potential, quantiﬁer MRM, qual-
iﬁer MRM, dwell time) are listed in Table 1. For the analysis of
incubations containing codeine and thebaine, separation of
(10 ll) samples was achieved by using a Gemini C18 octadecylsi-
lane HPLC column (Phenomenex, 5 lm, 150 mm  2 mm) com-
bined with a C18 guard column (Phenomenex, 4 mm  2 mm).
The mobile phase total ﬂow was set to 0.1 ml/min with binaryTable 1
Compound dependent parameters for the LC–MS/MS method.












Fig. 1. Conversion of thebaine and codeine by rat CYP2D1. (A) MRM for the substrate
product, m/z 298, after incubation of thebaine with CYP2D1. (C) MRM for the substrat
product, m/z 286, after incubation of codeine with CYP2D1. Illustrated is the sum of selgradient elution, using solvent A (0.2% acetic acid) and B (99.8%
CH3CN, 0.2% acetic acid) (all v/v). The gradient started with 100%
A for 5 min and was increased to 60% B over 20 min. Elution was
continued for 5 min at 60% B. A detailed description of the LC–
MS/MS analysis for reaction mixtures containing reticuline has
been published previously [8]. Incubations containing debrisoquine
were analyzed using an Eclipse XDB-C18 HPLC column combined
with a microﬁlter unit (Sigma, 1/16 OD tubing). The mobile phase
total ﬂow was set to 0.2 ml/min with binary gradient elution, using
solvent A (0.1% formic acid) and B (CH3CN). The gradient started
with 95% A for 2 min and was increased to 100% B over 8 min.
Elutionwas continued for 2 min at 100% B. Identiﬁcation of analytes
was based on retention times, MRM transition ratios, and compar-
ison with the expected values for standards. Quantitation was per-
formed by constructing standard curves for each analyte and
integrating the peak area of the quantiﬁer MRM transition with
Analyst 1.4.1 (Applied Biosystems, MDS SCIEX Instruments).
3. Results and discussion
Microsomal studies suggested rat P450 enzyme CYP2D1 as
functionally conserved with human CYP2D6 and an enzymatic cat-
alyst for the 3-O-demethylation reaction of thebaine and codeine
[6,7]. Thus, CYP2D1 was obtained from a commercial source and
tested in incubations containing these morphine precursors. Since
the 3-O-demethylation of thebaine, m/z 312, or codeine, m/z 300,
results in a mass loss of 14 mass units, speciﬁc multiple reaction
monitoring (MRM) for oripavine, m/z 298, and morphine, m/z
286, was selected. Minor product formation of m/z 298 was
observed in incubations with CYP2D1 and thebaine while codeine
was not converted by CYP2D1 (Fig. 1).
However, MS/MS data of the generated product m/z 298 were
not identical to the MS/MS obtained for the standard oripavine. ItQuantiﬁer MRM transition Qualiﬁer MRM transition Dwell time (ms)
330? 192 330? 137 50
328? 265 328? 282 50
328? 211 328? 237 50
328? 211 328? 237 50
328? 265 328? 237 50
312? 251 312? 281 50
298? 218 298? 249 50
300? 215 286? 225 50
286? 165 286? 201 50
176? 134 176? 117 100
192? 130 192? 115 100
thebaine, m/z 312, after incubation with CYP2D1. (B) MRM for the demethylated
e codeine, m/z 300, after incubation with CYP2D1. (D) MRM for the demethylated
ected MRM. Incubations were carried out for 120 min at 37 C.
Fig. 2. Identiﬁcation of product,m/z 298, formed from thebaine by CYP2D1. (A) MS/
MS of CYP2D1 product, m/z 298. (B) MS/MS of northebaine.
Fig. 3. Conversion of debrisoquine by rat CYP2D1 and CYP2D2. (A) MRM for the substr
hydroxydebrisoquine, m/z 192, after incubation of debrisoquine with CYP2D1. (C) MRM f
the product hydroxydebrisoquine,m/z 192, after incubation of debrisoquine with CYP2D2
37 C.
Fig. 4. Conversion of thebaine and codeine by rat CYP2D2. (A) MRM for the substrate
product, m/z 298, after incubation of thebaine with CYP2D2. (C) MS/MS of m/z 298 form
codeine, m/z 300, after incubation of CYP2D2. (F) MRM for the demethylated product, m/
codeine by CYP2D2. (H) MS/MS of morphine. Illustrated is the sum of selected MRM. Incu
converted to respective reaction products.
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to a possible CYP2D1-catalyzed demethylation of thebaine at the
ring nitrogen. Indeed, further comparison and mass spectrometric
characterization suggested the CYP2D1 product as N-demethylated
thebaine (Fig. 2). To conﬁrm that CYP2D1 was still active in incuba-
tions lasting as long as 120 min, the rat P450 enzyme was incu-
bated with the reference substrate, debrisoquine, as described
previously [10]. Indeed, as shown in Fig. 3A and B debrisoquine
was hydroxylated by CYP2D1 as previously described [9,10,15].
Using the same incubation conditions, it was again conﬁrmed that
CYP2D1 was not active with the morphine precursors.
Since CYP2D1 did not show similar catalytic activities to human
CYP2D6 in incubations with the alkaloidal substrates, we searchedate debrisoquine, m/z 176, after incubation with CYP2D1. (B) MRM for the product
or the substrate debrisoquine, m/z 176, after incubation with CYP2D2. (D) MRM for
. Illustrated is the sum of selected MRM. Incubations were carried out for 120 min at
thebaine, m/z 312, after incubation with CYP2D2. (B) MRM for the demethylated
ed from thebaine by CYP2D2. (D) MS/MS of oripavine. (E) MRM for the substrate
z 286, after incubation of CYP2D2 with codeine. (G) MS/MS of m/z 286 formed from
bations were carried out for 120 min at 37 C. Note that substrates were completely
Fig. 5. Test for phenol-coupling activities of CYP2D1 or CYP2D2. (A) MRM form/z 330 after incubation of CYP2D1 with (R)-reticuline. (B) MRM form/z 328 after incubation of
CYP2D1 with (R)-reticuline. (C) MRM for m/z 330 after incubation of CYP2D2 with (R)-reticuline. (D) MRM for m/z 328 after incubation of CYP2D2 with (R)-reticuline
(pallidine 8.92 min, corytuberine 10.25 min, salutaridine 12.58 min and isoboldine 13.44 min). Illustrated is the sum of selected MRM for all four products. Incubations were
carried out for 120 min at 37 C.
Table 2
Catalytic parameters for rat CYP2D2.
Substrate Product Km, lM kcat, pmol/min/pmol P450 kcat//Km, mM1 s1
(R)-reticuline Corytuberine 1.0 ± 0.18 0.03 ± 0.001 0.42
Pallidine 0.8 ± 0.10 0.86 ± 0.03 17.9
Salutaridine 0.7 ± 0.12 2.26 ± 0.11 53.9
Isoboldine 0.6 ± 0.10 0.69 ± 0.03 19.3
Thebaine Oripavine 42 ± 9.0 63 ± 7.6 25.0
Codeine Morphine 29 ± 4.6 14 ± 1.1 8.0
Table 3











nda/nda nda/nda 100/nda nda/nda
CYP2D6 [8] 4/2 23/17 7/5 66/76
CYP3A4 [8] 8/12 22/17 34/35 36/36
CYP2D2 [this work] 1/4 20/34 74/56 5/4
a nd: not detected.
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the 3-O-demethylation reaction of thebaine or codeine. Five iso-
forms were identiﬁed CYP2D2, CYP2D3, CYP2D4, CYP2D5 and
CYP2D18 among which rat CYP2D2, next to CYP2D1, was described
as poorly expressed in the Dark-Agouti rat strain [9]. Moreover,
studies with cDNA-expressed rat CYP isoforms elucidated that
CYP2D2, CYP2D4 and CYP2D18, but not CYP2D1, catalyzed the
hydroxylation of tyramine to dopamine with similar kinetic char-
acteristics for CYP2D2 compared with human CYP2D6 [11]. While
progesterone hydroxylation properties of CYP2D4 and CYP2D6
were alike [10,12], CYP2D2 and CYP2D6 resembled each other in
their catalytic activities for the hydroxylation of bufuralol, debr-
isoquine and propranolol, which are common CYP2D substrates
[10]. Thus, recombinant CYP2D2 was obtained from a commercial
source and tested ﬁrst with debrisoquine to conﬁrm activity. Sim-
ilar to rat CYP2D1, CYP2D2 converted debrisoquine to hydroxy-
debrisoquine in incubations as long as 120 min (Fig. 3C and D).
Moreover, as shown in Fig. 4 CYP2D2 was highly active with both
morphine precursors, thebaine and codeine, using the same incu-
bation conditions. The reaction products at m/z 298 and m/z 286
showed identical MS/MS spectra upon comparison to oripavine
and morphine standards, respectively (Fig. 4).
After conﬁrming 3-O-demethylating activity for CYP2D2 with
thebaine and codeine, the phenol coupling reaction of (R)-reticuline
was examined and enzymatic activities of rat CYP2D1 and CYP2D2towards this third morphine precursor were compared. Since the
mechanism of the phenol-coupling reaction of (R)-reticuline, m/z
330, leads to a total loss of 2 mass units, the MRM for m/z 328 was
monitored. Fig. 5 illustrates that while CYP2D1 was inactive,
CYP2D2 formed the four expected products corytuberine, pallidine,
salutaridine and isoboldine. Using (R)-reticuline as substrate, an
optimal pH of 7.4was determined for CYP2D2. The relative distribu-
tion of the four phenol-coupled products was the same after 10 and
120 min of incubation as well as at any pH between 5 and 9.
Michaelis–Menten kinetic parameters revealed that, similar to
human CYP2D6, rat CYP2D2 shows a higher Km value for thebaine
and codeine (29–46 lM) in comparison with (R)-reticuline (0.6–
1.0 lM) (Table 2). However, catalytic efﬁciencies for all three sub-
strates became similar due to lower maximum rates (kcat) for the
conversion of (R)-reticuline. Overall catalytic efﬁciencies for theba-
ine, codeine and (R)-reticuline were at least an order of magnitude
higher than for human CYP2D6 (Table 2 and [8]).
Including this work, four enzymes are known to catalyze the
intramolecular formation of the critical C12–C13 bridge in salutari-
dine during morphine biosynthesis [8,13,14]. Table 3 compares the
relative capacity of these four cytochrome P450s to catalyze the
formation of phenol-coupled products from reticuline. While plant
salutaridine synthase only generates salutaridine and does not
accept the (S)-enantiomer as substrate, the mammalian P450
enzymes appear to be more promiscuous. Among all, rat CYP2D2
N. Grobe et al. / FEBS Letters 586 (2012) 1749–1753 1753is the most efﬁcient mammalian P450 enzyme to produce the crit-
ical morphine precursor.
In conclusion, new enzymatic activities were found for rat
CYP2D2 that have been incorrectly proposed for CYP2D1. A similar
correction of CYP2D1/CYP2D2 has previously been made for the
drugdebrisoquine [9,15]. Theseﬁndingsbecomeparticularly impor-
tant for studies relying on results based on comparison of enzyme
activities betweendifferent rat strains [6,7,16–20]. Thus, themetab-
olism of some drugs, such as metoprolol, dextromethophan or 3,4-
methylenedioxymethamphetamine, might need further evaluation.
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